Literature DB >> 22952040

Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.

Peter Ouillette1, Jinghui Li, Rita Shaknovich, Yifeng Li, Ari Melnick, Kerby Shedden, Sami N Malek.   

Abstract

A subset of chronic lymphocytic leukemia (CLL) carries mutations in ataxia telangiectasia mutated (ATM). Such ATM mutations may be particularly relevant in the setting of del11q, which invariably results in the deletion of one ATM allele. To improve our understanding of the frequency and type of ATM mutations that exist in CLL, we resequenced all ATM coding exons in 24 CLL with del11q using direct sequencing. We detected two missense mutations, resulting in an ATM mutation frequency of 8%; nonsense and frameshift mutations were not identified. Given the low ATM mutation frequency detected in this cohort, we proceeded with measurements of nonmutational ATM aberrations in CLL through analysis of the activation state of ATM in response to external irradiation. The phosphorylation state of ATM at Ser-1981 was measured using quantitative immunoblotting in purified CLL cells isolated from 251 CLL patients; data were normalized to simultaneous measurements of total ATM protein and actin. Resulting p-ATM/ATM and p-ATM/actin ratios were subsequently analyzed for prognostic significance inclusive and exclusive of TP53 exons 2-10 mutations. From these analyses, conducted in a large prospectively enrolled CLL patient cohort, neither the p-ATM/ATM nor the p-ATM/actin ratios were found to be prognostic for short survival. These data in aggregate demonstrate a low frequency of ATM aberrations in an unselected CLL cohort and do not support a major prognostic role for ATM aberrations in CLL, thus motivating renewed research efforts aimed at understanding the pathobiology of 11q deletions in CLL. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22952040      PMCID: PMC3465492          DOI: 10.1002/gcc.21997

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  24 in total

1.  ATM mutations in B-cell chronic lymphocytic leukemia.

Authors:  F Bullrich; D Rasio; S Kitada; P Starostik; T Kipps; M Keating; M Albitar; J C Reed; C M Croce
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

2.  Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.

Authors:  Gerard Lozanski; Amy S Ruppert; Nyla A Heerema; Arletta Lozanski; David M Lucas; Amber Gordon; John G Gribben; Vicki A Morrison; Kanti M Rai; Guido Marcucci; Richard A Larson; John C Byrd
Journal:  Leuk Lymphoma       Date:  2012-06-02

3.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.

Authors:  C Schaffner; S Stilgenbauer; G A Rappold; H Döhner; P Lichter
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

4.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

Authors:  Belinda Austen; Judith E Powell; Azra Alvi; Ian Edwards; Laura Hooper; Jane Starczynski; A Malcolm R Taylor; Christopher Fegan; Paul Moss; Tatjana Stankovic
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

5.  Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease.

Authors:  C Fegan; H Robinson; P Thompson; J A Whittaker; D White
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

6.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

7.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.

Authors:  G Juliusson; D G Oscier; M Fitchett; F M Ross; G Stockdill; M J Mackie; A C Parker; G L Castoldi; A Guneo; S Knuutila; E Elonen; G Gahrton
Journal:  N Engl J Med       Date:  1990-09-13       Impact factor: 91.245

8.  Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia.

Authors:  T Stankovic; P Weber; G Stewart; T Bedenham; J Murray; P J Byrd; P A Moss; A M Taylor
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

9.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation.

Authors:  Christopher J Bakkenist; Michael B Kastan
Journal:  Nature       Date:  2003-01-30       Impact factor: 49.962

10.  Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.

Authors:  P Starostik; T Manshouri; S O'Brien; E Freireich; H Kantarjian; M Haidar; S Lerner; M Keating; M Albitar
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

View more
  13 in total

Review 1.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

Review 2.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

3.  ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Authors:  Matthew J J Rose-Zerilli; Jade Forster; Helen Parker; Anton Parker; Ana E Rodríguez; Tracy Chaplin; Anne Gardiner; Andrew J Steele; Andrew Collins; Bryan D Young; Anna Skowronska; Daniel Catovsky; Tatjana Stankovic; David G Oscier; Jonathan C Strefford
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

4.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 5.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

6.  Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.

Authors:  Patricia T Greipp; Stephanie A Smoley; David S Viswanatha; Lori S Frederick; Kari G Rabe; Ruchi G Sharma; Susan L Slager; Daniel L Van Dyke; Tait D Shanafelt; Renee C Tschumper; Clive S Zent
Journal:  Br J Haematol       Date:  2013-08-27       Impact factor: 6.998

Review 7.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

8.  The spectrum of genetic defects in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Marco Fangazio; Gianluca Gaidano
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-11-13       Impact factor: 2.576

Review 9.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

10.  Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.

Authors:  Jiguang Wang; Hossein Khiabanian; Davide Rossi; Giulia Fabbri; Valter Gattei; Francesco Forconi; Luca Laurenti; Roberto Marasca; Giovanni Del Poeta; Robin Foà; Laura Pasqualucci; Gianluca Gaidano; Raul Rabadan
Journal:  Elife       Date:  2014-12-11       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.